BTIG analyst Sean Lavin expects shares of Exact Sciences to rally further following the leak yesterday of a JAMA article. Assuming the article is published and reflects the U.S. Preventive Services Task Force's updated views, the guidelines will help Exact obtain routine reimbursement more quickly than the company may have under the previous recommendation, Lavin tells investors in a research note. The update, while not perfect, is a "major positive" for the company, the analyst contends. Lavin has a Buy rating on Exact Sciences with a $9 price target. Following yesterday's 33% rally, the stock is up an additional 14% to $10.72 in pre-market trading.